Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer
作者： Andrew Weickhardt
DOI:
关键词:
摘要: Given the high cost, optimizing survival of patients with colorectal cancer requires research into two important questions. Firstly, can there be improved efficacy these agents by using novel combinations existing or other new drugs? Secondly, what are mechanisms both innate and acquired resistance to Restricting use from those who have factors that govern immediate will enrich maximise initial response rates (RR). Identification governing may allow future strategies avoid ongoing durable responses therapy. This thesis aims explore methods targeted treatment EGFR pathway VEGF related in cancer. The biology each reviewed. Therapeutic options for inhibiting pathways discussed, focusing on agents. concept maximising effect targeting drugs target same Additionally, biological characteristics tumour predict individual also
参考文章(401)
Alan N. Houghton, David A. Scheinberg, Monoclonal antibody therapies-a 'constant' threat to cancer. Nature Medicine. ,vol. 6, pp. 373- 374 ,(2000) , 10.1038/74621
M. G. Zampino, K. Lorizzo, C. Massacesi, A. Rizzi, S. Crispino, S. Boselli, G. Pelosi, L. Zorzino, N. Fazio, F. de Braud, First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer Journal of Clinical Oncology. ,vol. 23, pp. 3659- 3659 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3659
Scott Kopetz, Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic Gastrointestinal cancer research : GCR. ,vol. 1, ,(2007)
A. Jimeno, I. Sevilla, C. Gravalos, M. E. Vega, P. Escudero, E. Torre, F. Rivera, M. L. Garcia de Paredes, R. Colomer, H. Cortes-Funes, Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy Journal of Clinical Oncology. ,vol. 23, pp. 3176- 3176 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3176
Mario E. Lacouture, Lynne I. Wagner, Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology. ,vol. 21, pp. 34- 35 ,(2007)
Sarah J Parsons, Role of c-Src tyrosine kinase in EGF-induced mitogenesis Frontiers in Bioscience. ,vol. 2, pp. d501- 518 ,(1997) , 10.2741/A208
Rodney Luwor, Lauren Taylor, Bo Wang, Hong-Jian Zhu, Tumor-associated EGFR over-expression specifically activates Stat3 and Smad7 resulting in desensitization of TGF-E signaling Nature Precedings. ,(2008) , 10.1038/NPRE.2008.1535.1
Pornchai O-charoenrat, Peter Rhys-Evans, William J. Court, Gary M. Box, Suzanne A. Eccles, Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands. Clinical & Experimental Metastasis. ,vol. 17, pp. 631- 639 ,(1999) , 10.1023/A:1006751016860
Stefano Cascinu, Francesco Graziano, Vincenzo Catalano, Maria Pia Staccioli, Sandro Barni, Paolo Giordani, Maria Cristina Rossi, Anna Maria Baldelli, Pietro Muretto, Andrea Valenti, Giuseppina Catalano, Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clinical & Experimental Metastasis. ,vol. 18, pp. 651- 655 ,(2000) , 10.1023/A:1013133224044
C. Greenfield, I. Hiles, M.D. Waterfield, M. Federwisch, A. Wollmer, T.L. Blundell, N. McDonald, Epidermal growth factor binding induces a conformational change in the external domain of its receptor. The EMBO Journal. ,vol. 8, pp. 4115- 4123 ,(1989) , 10.1002/J.1460-2075.1989.TB08596.X